- Home
- CYD vs TNGX Comparison
CYD vs TNGX Comparison
Compare CYD & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYD
- TNGX
- Stock Information
- Founded
- CYD 1951
- TNGX 2014
- Country
- CYD Singapore
- TNGX United States
- Employees
- CYD N/A
- TNGX N/A
- Industry
- CYD Industrial Machinery/Components
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CYD Industrials
- TNGX Health Care
- Exchange
- CYD Nasdaq
- TNGX Nasdaq
- Market Cap
- CYD 493.2M
- TNGX 413.6M
- IPO Year
- CYD 1994
- TNGX N/A
- Fundamental
- Price
- CYD $9.42
- TNGX $3.63
- Analyst Decision
- CYD
- TNGX Strong Buy
- Analyst Count
- CYD 0
- TNGX 8
- Target Price
- CYD N/A
- TNGX $13.14
- AVG Volume (30 Days)
- CYD 18.9K
- TNGX 3.5M
- Earning Date
- CYD 08-12-2024
- TNGX 11-06-2024
- Dividend Yield
- CYD 4.14%
- TNGX N/A
- EPS Growth
- CYD 14.53
- TNGX N/A
- EPS
- CYD 1.17
- TNGX N/A
- Revenue
- CYD $2,639,608,357.00
- TNGX $43,383,000.00
- Revenue This Year
- CYD $11.68
- TNGX $25.55
- Revenue Next Year
- CYD $4.06
- TNGX N/A
- P/E Ratio
- CYD $7.82
- TNGX N/A
- Revenue Growth
- CYD 15.32
- TNGX 15.67
- 52 Week Low
- CYD $7.85
- TNGX $2.70
- 52 Week High
- CYD $13.05
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- CYD 28.75
- TNGX 34.67
- Support Level
- CYD $8.91
- TNGX $3.54
- Resistance Level
- CYD $9.55
- TNGX $4.14
- Average True Range (ATR)
- CYD 0.45
- TNGX 0.51
- MACD
- CYD -0.09
- TNGX 0.11
- Stochastic Oscillator
- CYD 17.86
- TNGX 35.84
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.